id: smoking_cessation_treatment_use_to_NEW:neuropsychiatric_adverse_events
name: Smoking Cessation Treatment Use â†’ Neuropsychiatric Adverse Events
from_node:
  node_id: smoking_cessation_treatment_use
  node_name: Smoking Cessation Treatment Use
to_node:
  node_id: NEW:neuropsychiatric_adverse_events
  node_name: Neuropsychiatric Adverse Events
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: Access to smoking cessation medicines (varenicline, bupropion, NRT, e-cigarettes) enables quit
  attempts'
- 'Step 2: Pharmacological agents act on nicotinic acetylcholine receptors and neurotransmitter systems'
- 'Step 3: Alterations in dopaminergic and serotonergic pathways may produce neuropsychiatric effects'
- 'Step 4: Some patients experience serious adverse events including psychiatric symptoms requiring hospitalization'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: Kyla H Thomas et al. 2017. "How do smoking cessation medicines compare with respect
    to their neuropsychiatric safety? A protocol for a systematic review, network meta-analysis and cost-effectiveness
    analysis.." https://doi.org/10.1136/bmjopen-2016-015414
  supporting_citations:
  - Additional citations require full-text access - this is a protocol paper for a systematic review
  - Previous reviews on smoking cessation medicines referenced in protocol
  - Studies comparing varenicline, bupropion, and NRT safety profiles
  doi: 10.1136/bmjopen-2016-015414
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: This protocol outlines a systematic review to compare neuropsychiatric safety of smoking
  cessation medicines. The primary outcome is serious adverse events (death, life-threatening events,
  hospitalization, significant disability). The study will examine whether structural access to these
  medicines through healthcare systems carries differential risks.
moderators:
- name: type_of_cessation_medicine
  direction: strengthens
  strength: moderate
  description: Different cessation medicines (varenicline, bupropion, NRT, e-cigarettes) may have differential
    neuropsychiatric safety profiles
- name: combination_therapy
  direction: strengthens
  strength: weak
  description: Combination therapies compared to monotherapy may have different safety profiles
structural_competency:
  equity_implications: Public health guidance recommending specific cessation medicines creates structural
    pathways to medication access. Safety concerns may differentially affect populations with pre-existing
    mental health conditions or limited healthcare access for monitoring. The protocol aims to inform
    equitable prescribing guidelines.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:36.364119'
  extraction_confidence: low
  prompt_version: 2.1-canonical-validated
